Blueprint Medicines Corp (NASDAQ:BPMC)
| 72.01 Delayed Data As of Dec 01 |  +2.37 / +3.40%Today’s Change | 37.82 Today|||52-Week Range 72.14 | +64.37% Year-to-Date |
Latest BPMC News | Press Releases
| Why Is Glaxo (GSK) Up 5.3% Since Last Earnings Report? Dec 01 / Zacks.com - Paid Partner Content | Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 1.7% Since Last Earnings Report? Nov 29 / Zacks.com - Paid Partner Content |
| Repligen (RGEN) Up 21.3% Since Last Earnings Report: Can It Continue? Nov 30 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 69.64 |
| Today’s open | 68.87 |
| Day’s range | 68.30 - 72.02 |
| Volume | 21,222 |
| Average volume (3 months) | 682,928 |
| Market cap | $4.3B |
Data as of 3:59pm ET, 12/01/2023
Growth & Valuation
| Earnings growth (last year) | +15.07% |
| Earnings growth (this year) | -3.58% |
| Earnings growth (next 5 years) | +34.00% |
| Revenue growth (last year) | +13.30% |
| P/E ratio | NM |
| Price/Sales | 12.81 |
| Price/Book | 8.33 |
Financials
| Next reporting date | February 15, 2024 |
| EPS forecast (this quarter) | -$2.47 |
| Annual revenue (last year) | $204.0M |
| Annual profit (last year) | -$557.5M |
| Net profit margin | -273.24% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
